Developing revised NICE Appraisal Technical Guidance to Manufacturers and Sponsors: opportunity or threat?

Rodney Taylor

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    One of the principal roles of the National Institute for Clinical Excellence (NICE) is to appraise selected existing and emerging healthcare technologies and, as a result, produce guidance for the National Health Service (NHS) in England and Wales. A central part of this appraisal is the potential for manufacturers and sponsors to make a data submission. This paper describes the process of development of the second edition of technical guidance to manufacturers and sponsors for submission to NICE. The revision process took place during the period May 2000 and January 2001 and involved a number of key steps -- establishment of a guidance steering committee, review of current international guidelines of clinical and cost effectiveness, drafting of the guidance, detailed consultation with stakeholders, revision of the guidance and, finally, publication. The lessons learnt from revision of the NICE guidance for manufacturers and sponsors and some main issues for its future development are discussed.
    Original languageEnglish
    Pages (from-to)1031-1038
    Number of pages8
    JournalPharmacoEconomics
    Volume20
    Issue number15
    DOIs
    Publication statusPublished - 1 Jan 2002

    Fingerprint

    Dive into the research topics of 'Developing revised NICE Appraisal Technical Guidance to Manufacturers and Sponsors: opportunity or threat?'. Together they form a unique fingerprint.

    Cite this